Molecular Insight's research and development strategy is focused on applying its proprietary platform technologies to develop innovative molecular imaging pharmaceuticals and targeted radiotherapeutics for growing markets with significant unmet clinical and medical needs.

The company augments its internal discoveries and capabilities by collaborating with leading biomedical research institutions. These include: the University of Maryland, McLean Hospital, University of Western Ontario, McMaster University and Syracuse University. Molecular Insight's research efforts have been further supported by more than 25 N.I.H. grants over the last six years.

This research and development strategy has resulted in a significant pipeline of novel product candidates, both molecular imaging and targeted radiotherapeutics, that address the large and growing areas of cardiology, oncology and neurology. The company has 12 issued patents with numerous ex-U.S. counterpart patent applications and 8 pending U.S. patents with ex-U.S. counterpart applications.